Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Small study tests best way to mix chemo for liver tumors

NCT ID NCT03706157

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researchers took small tissue samples and used special imaging to track the drug, aiming to find the best way to prepare the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

10 people

The number who actually took part.

Started

Nov 2018

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (\>18) * Informed consent * CHC Child-Pugh stage A or B, BCLC stage B * Referred for chemoembolization of a non-surgery-candidate CHC * Blood test results compatible with cTACE (INR ≤ 1,5, ASAT/ALAT\<5N, albumine\>2,5g/dl) Exclusion Criteria: * Contraindication to cTACE, angiography, confocal laser endomicroscopy or liver biopsy Hyperthyroidism * Contraindication to the use of fluorescein, Ariblastine,Lipiodol, Visipaque, Gelita spon, Avitene * extra hepatic metastasis * Subcapsular or exophytic tumor impeding direct percutaneous access through healthy liver tissue * Waiting list for liver transplant * Complete portal venous thrombosis or flow inversion * Pregnancy or breast feeding * Protected major (Guardianship) * Patient in situation of exclusion (determined by a previous or ongoing study) * Subject incapacity to understand informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepato-cellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepato-cellular carcinoma

Contacts and locations

Locations

  • University Hospital, Strasbourg, france

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.